THE OBJECTIVE OF THIS PROJECT IS TO PRODUCE AND CHARACTERIZE SOME SPECIFIC MURINE MONOCLONAL ANTIBODIES AGAINST DYNORPHIN A (117) AND DYNORPHIN B (113) (OR RIMORPHIN).

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$37,978.00
Award Year:
1985
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Award Id:
3358
Agency Tracking Number:
3358
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
6501 Fannin,c506,, Houston, TX, 77030
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
SEKCHUNG FUNG
PRINCIPAL INVESTIGATOR
(945) 387-6418
Business Contact:
() -
Research Institute:
n/a
Abstract
THE OBJECTIVE OF THIS PROJECT IS TO PRODUCE AND CHARACTERIZE SOME SPECIFIC MURINE MONOCLONAL ANTIBODIES AGAINST DYNORPHIN A (117) AND DYNORPHIN B (113) (OR RIMORPHIN). THE HYBRIDOMAS THUS RAISED WILL BE USED AS CONSISTENT AND COST-EFFECTIVE SOURCES OF THE SPECIFIC MONOCLONAL ANTIBODIES WHICH WILL SUPERSEDE THE ANTISERA CURRENTLY PRODUCED BY SOME RESEARCH GROUPS. USING RADIOIMMUNOASSAY (RIA) AND SOLID-PHASE ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), THESE MONOCLONAL ANTIBODIES CAN BE WIDELY APPLIED FOR THE QUANTITATION OF THE DYNORPHINS IN BOTH NORMAL AND DISEASED NEURAL TISSUES. THESE ANTIBODIES CAN ALSO BE UTILIZED FOR THE LOCALIZATION OF DYNORPHIN-IMMUNOREACTIVE PATHWAYS IN THE NERVOUS SYSTEM USING IMMUNOCYTOCHEMISTRY. THE LONG-TERM GOAL OF THIS STUDY IS TO PROVIDE A BETTER IMMUNOLOGICAL MEANS TO ELUCIDATE THE MECHANISMS OF PROCESSING OF PROENKEPHALIN B AND THE METABOLISM OF DYNORPHINS IN DIFFERENT ANIMAL SPECIES, WITH REGARD TO THEIR POSSIBLE ROLE IN NEUROTRANSMISSION AND NEUROMODULATION. FURTHERMORE, THE FUNCTIONAL SIGNIFICANCE AND THE DIFFERENTIAL ACTIONS OF DYNORPHIN A AND DYNORPHIN B IN THE PHYSIOLOGY OF ANALGESIA, SEDATION, VISCERAL REFLEX, AND NEUROENDOCRINE REGULATION CAN BE EXAMINED. IN THIS PROPOSED STUDY, BALB/C MICE WILL BE IMMUNIZED WITH DYNORPHINS CONJUGATED TO THYROGLOBULIN FOR A MONTH, AND THE IMMUNE SPLEEN CELLS THEN ISOLATED FOR IN VITRO IMMUNIZATION FOR 4 DAYS. THE LYMPHOCYTES ARE THEN FUSED WITH MYELOMA CELLS (P3 63AG8.653); THE HYBRIDOMAS WILL BE ISOLATED BY HAT MEDIUM AND CLONED. THE MONOCLONAL ANTIBODIES ARE SCREENED FOR TITER AND TYPED FOR SUBCLASSES, USING ELISA, AND FOR THE DEGREE OF CROSS-REACTIVITY WITH OTHER RELATED OPIOID PEPTIDES, USING RIA. THE SPECIFIC MONOCLONAL ANTIBODIES WILL BE PRODUCED FROM ASCITES FLUID BY INJECTING THE HYBRIDOMAS INTO BALB/C MICE, AND PURIFIED BY HYDROXYLAPATITE COLUMN CHROMATOGRAPHY. THE SPECIFIC HYBRIDOMA CELLS WILL BE STORED FROZEN AS PERMANENT SOURCES OF THE ANTIBODIES.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government